Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 21

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
 millions, except per share data)20252024Basic EPSNet earnings attributable to AbbVie Inc.$1,286 $1,369 Earnings allocated to participating securities10 10 Earnings available to common shareholders$1,276 $1,359 Weighted-average basic shares outstanding1,768 1,769 Basic earnings per share attributable to AbbVie Inc.$0.72 $0.77 Diluted EPSNet earnings attributable to AbbVie Inc.$1,286 $1,369 Earnings allocated to participating securities10 10 Earnings available to common shareholders$1,276 $1,359 Weighted-average shares of common stock outstanding1,768 1,769 Effect of dilutive securities4 4 Weighted-average diluted shares outstanding1,772 1,773 Diluted earnings per share attributable to AbbVie Inc.$0.72 $0.77 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

2025 Form 10-Q | 7

Note 4 Licensing, Acquisitions and Other Arrangements 

Acquisition of Nimble Therapeutics, Inc.On January 23, 2025, AbbVie completed its acquisition of Nimble Therapeutics, Inc. (Nimble). Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics and its lead asset, an investigational oral peptide IL23R inhibitor, is in preclinical development for the treatment of psoriasis. The aggregate purchase price of $288 million was comprised of a $210 million upfront cash payment and $78 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $130 million in future payments upon achievement of certain development milestones. The transaction was accounted for as a business combination using the acquisition method of accounting. As of the acquisition date, AbbVie acquired $118 million of intangible assets and resulted in the recognition of $170 million of goodwill. Goodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized, including expected synergies related to enhancement of AbbVie’s existing immunology discovery capabilities and development efforts. The goodwill is not deductible for